This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate.  The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess.  Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.   Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

The folks at Eli Lilly probably cringe every time I go here, but the company this morning reported that third quarter U.S. sales of the erectile dysfunction drug Cialis sprung 13 percent to nearly $159 million.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

Following my post earlier this week on the highest yielding stocks in the Dow, here is a deeper look at the dividends of the S&P 500.   Read More

Dendreon is growing in more ways than one. At a time when so many drug companies are letting people go, Dendreon is on a hiring binge to ramp up for the anticipated launch of its prostate cancer drug Provenge. But it's also expanding its board of directors.    Read More

The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.    Read More

Both the Dow and S&P closed in positive territory with optimism about potential M&A deals trumping concerns about trade friction between the United States and China.   Read More

Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.    Read More